What is Perfuze?
Founded in 2018, Perfuze is a specialized medical technology company dedicated to addressing the unmet clinical needs in stroke treatment. The firm focuses on the development of innovative catheter technology that enhances vessel access and optimizes clot removal during complex thrombectomy procedures. By prioritizing repeatable and effective methods for neurovascular intervention, Perfuze has established itself as a key player in the medtech sector, bridging the gap between complex surgical requirements and patient-centric outcomes. Their commitment to engineering excellence and clinical efficacy has attracted significant interest from institutional investors focused on high-impact healthcare innovation.
How much funding has Perfuze raised?
Perfuze has raised a total of $51.9M across 3 funding rounds:
Angel/Seed
$2.4M
Series A
$25.7M
Unspecified
$23.8M
Angel/Seed (2019): $2.4M, investors not publicly disclosed
Series A (2022): $25.7M led by LSP, Seroba Life Sciences Management, and SV Health Investors
Unspecified (2025): $23.8M supported by SV Health Investors, EQT, Earlybird, and Seroba
Key Investors in Perfuze
SV Health Investors
SV Health Investors is a specialist investment firm backing innovative health care and life science companies, partnering with founders and management to provide capital, sector expertise and active support from early growth through scale and value creation.
EQT
EQT Private Capital is a global investment platform focused on partnering with companies across their development stages, applying a thematic and sector-focused approach with deep expertise in healthcare and industrial technology.
Seroba
Seroba is a European life sciences venture capital firm based in Dublin and Paris, focusing on value creation through backing cutting-edge biotech and medtech innovation that transforms the treatment of unmet medical needs.
What's next for Perfuze?
With this major strategic investment, Perfuze is poised to enter a new phase of enterprise-level expansion. The company is expected to leverage these funds to broaden its clinical reach, enhance its manufacturing capabilities, and potentially accelerate the regulatory pathways for its next-generation thrombectomy devices. As the demand for more efficient stroke treatment solutions continues to rise globally, Perfuze's focus on technological precision and clinical reliability will be central to its long-term market strategy. The firm remains committed to its core objective of improving human health through the deployment of advanced medical technology, ensuring that its solutions become a standard of care in neurovascular procedures.
See full Perfuze company page
